Lataa...
Long-term Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) who Discontinue Ibrutinib
INTRODUCTION: Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, approved for the treatment of patients with chronic lymphocytic leukemia in frontline and relapsed-refractory settings. We previously reported poor outcomes for patients discontinuing ibrutinib; however, long term outcomes were n...
Tallennettuna:
| Julkaisussa: | Cancer |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5980235/ https://ncbi.nlm.nih.gov/pubmed/28171709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30596 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|